Related Experiment Video
Updated: May 19, 2026
12:21
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
Selective serotonin reuptake inhibitors in pregnancy
V Bellissima1, T F F Ververs, G H A Visser
1Cesare Arrigo Children's Hospital, Alessandria, Italy.
Current Medicinal Chemistry
|August 11, 2012
Summary
Selective serotonin reuptake inhibitors (SSRIs) use in pregnancy is debated, with potential risks to fetal development. Treatment decisions require balancing risks against untreated maternal depression, favoring alternatives for milder cases.
Area of Science:
- Perinatology
- Pharmacology
- Developmental Toxicology
Background:
- Antenatal exposure to selective serotonin reuptake inhibitors (SSRIs) is increasing.
- The safety and effects of SSRIs during pregnancy remain controversial.
- Existing research presents conflicting findings regarding teratogenicity and developmental impacts.
Purpose of the Study:
- To review the existing literature on the effects of SSRIs on embryonic, fetal, and infant development.
- To provide a balanced perspective on SSRI use during pregnancy.
Main Methods:
- Comprehensive literature review of studies on SSRI exposure during pregnancy.
- Analysis of data concerning congenital malformations, fetal behavior, and neonatal outcomes.
Main Results:
- Some studies indicate SSRIs are not teratogenic, while others report increased congenital malformations.
- Antenatal SSRI exposure can affect fetal behavior, with 30% of infants experiencing neonatal withdrawal.
- Long-term developmental sequelae following in utero SSRI exposure are not yet fully excluded.
Conclusions:
- Clear guidelines for SSRI treatment in pregnancy are lacking.
- Risk-benefit assessment is crucial, balancing SSRI exposure against untreated maternal depression.
- SSRIs should be reserved for necessary cases; alternative treatments are recommended for milder depression.
Related Concept Videos
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...